Novo Nordisk’s gamechanger drug

Pharma News: One third (35%) of people who took Novo Nordisk new drug lost more than one-fifth (greater than or equal to 20%) of their total body weight, according to a major global study.

The findings from the large-scale international phase 3 trial, published in the New England Journal for Medicine, is a “gamechanger” for improving the health of people with obesity and could play a major part in helping to reduce the impact of diseases, such as COVID-19.

Novo Nordisk’s Ozempic (semaglutide), GLP-1 agonist, works by hijacking the body’s own appetite regulating system in the brain leading to reduced hunger and calorie intake, and treat obesity.

Professor Rachel Batterham, one of the principal authors said “The findings of this study represent a major breakthrough for improving the health of people with obesity. Three quarters (75%) of people who received semaglutide 2.4mg lost more than 10% of their body weight and more than one-third lost more than 20%. No other drug has come close to producing this level of weight loss – this really is a gamechanger. For the first time, people can achieve through drugs what was only possible through weight-loss surgery.”

Professor Batterham added “The impact of obesity on health has been brought into sharp focus by COVID-19 where obesity markedly increases the risk of dying from the virus, as well as increasing the risk of many life-limiting serious diseases including heart disease, type 2 diabetes, liver disease and certain types of cancers. This drug could have major implications for UK health policy for years to come.”

The average participant in the trial lost 15.3kg. This was accompanied by reductions in risk factors for heart disease and diabetes, such as waist circumference, blood fats, blood sugar and blood pressure and reported improvements in their overall quality of life.

The trial’s UK Chief Investigator, Professor John Wilding (University of Liverpool) said “This is a significant advance in the treatment of obesity. Semaglutide is already approved and used clinically at a lower dose for treatment of diabetes, so as doctors we are already familiar with its use. For me this is particularly exciting as I was involved in very early studies of GLP1 (when I worked at the Hammersmith Hospital in the 1990s we were the first to show in laboratory studies that GLP1 affected appetite), so it is good to see this translated into an effective treatment for people with obesity.”

With evidence from this trial, semaglutide has been submitted for regulatory approval as a treatment for obesity to the National Institute of Clinical Excellence (NICE), the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

In Australia , Ozempic injection is currently reimbursed as of July 2020 for the treatment of adults with insufficiently controlled type 2 diabetes.